NASDAQ:PRTA Prothena (PRTA) Stock Price, News & Analysis $16.80 +0.12 (+0.72%) (As of 10/3/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Prothena Stock (NASDAQ:PRTA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Prothena alerts:Sign Up Key Stats Today's Range$16.13▼$16.8350-Day Range$16.65▼$24.4352-Week Range$15.52▼$55.89Volume737,643 shsAverage Volume600,698 shsMarket Capitalization$903.50 millionP/E RatioN/ADividend YieldN/APrice Target$61.86Consensus RatingModerate Buy Company OverviewProthena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.Read More… Retire off just one stock ticker? (Ad)ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT make you rich. However, there is one stock that stands head and shoulders above everything else. It's currently trading for only $15...Click here for the ticker >>> Prothena Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks57th Percentile Overall ScorePRTA MarketRank™: Prothena scored higher than 57% of companies evaluated by MarketBeat, and ranked 501st out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingProthena has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageProthena has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Prothena's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Prothena are expected to decrease in the coming year, from ($2.31) to ($4.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prothena is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prothena is -5.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProthena has a P/B Ratio of 1.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Prothena's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.64% of the outstanding shares of Prothena have been sold short.Short Interest Ratio / Days to CoverProthena has a short interest ratio ("days to cover") of 14.9, which indicates bearish sentiment.Change versus previous monthShort interest in Prothena has recently increased by 2.33%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProthena does not currently pay a dividend.Dividend GrowthProthena does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.64% of the outstanding shares of Prothena have been sold short.Short Interest Ratio / Days to CoverProthena has a short interest ratio ("days to cover") of 14.9, which indicates bearish sentiment.Change versus previous monthShort interest in Prothena has recently increased by 2.33%, indicating that investor sentiment is decreasing. News and Social Media2.4 / 5News Sentiment0.28 News SentimentProthena has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Prothena this week, compared to 3 articles on an average week.Search Interest4 people have searched for PRTA on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Prothena to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Prothena insiders have not sold or bought any company stock.Percentage Held by Insiders28.20% of the stock of Prothena is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.08% of the stock of Prothena is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Prothena's insider trading history. Receive PRTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTA Stock News HeadlinesMaintaining Hold on Prothena Amid Executive Changes and Clinical Validation NeedsOctober 2 at 5:00 AM | markets.businessinsider.comProthena (NASDAQ:PRTA) Receives Buy Rating from HC WainwrightOctober 2 at 4:01 AM | americanbankingnews.comTrade Alongside Pelosi, Buffett, and MorePeople don't know that you can trade alongside politicians, lawmakers, and top investors like Warren Buffet, Bill Ackman, Steve Cohen and more. They also don’t know that they can learn how it’s done and receive daily, AI powered trade alerts for free! All because of one trading veteran that set up a free newsletter designed to level the playing field.October 4, 2024 | Bullseye Trades (Ad)Prothena (NASDAQ:PRTA) Price Target Lowered to $31.00 at Bank of AmericaOctober 2 at 4:01 AM | americanbankingnews.comBreaking Down Prothena Corp: 4 Analysts Share Their ViewsOctober 1 at 6:58 PM | benzinga.comProthena Buy Rating Affirmed: Leadership Changes and Prasinezumab’s Promise Signal Investment OpportunityOctober 1 at 6:58 PM | markets.businessinsider.comProthena Corp (NASDAQ:PRTA) Stock, Insider Trading ActivityOctober 1 at 5:26 AM | benzinga.comDow Dips 300 Points; Emcore Shares Spike HigherSeptember 30, 2024 | benzinga.comSee More Headlines PRTA Stock Analysis - Frequently Asked Questions How have PRTA shares performed this year? Prothena's stock was trading at $36.34 at the beginning of the year. Since then, PRTA stock has decreased by 53.8% and is now trading at $16.80. View the best growth stocks for 2024 here. How were Prothena's earnings last quarter? Prothena Co. plc (NASDAQ:PRTA) released its quarterly earnings results on Thursday, August, 8th. The biotechnology company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of ($1.01) by $2.23. The firm's quarterly revenue was up 3184.7% compared to the same quarter last year. Who are Prothena's major shareholders? Prothena's top institutional investors include Duncan Williams Asset Management LLC (0.09%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Ecor1 Capital, Llc, Gene G Kinney, Tran Nguyen, Dennis J Selkoe, Richard T Collier, Lars Ekman, Michael J Malecek, Karin L Walker, Hideki Garren, Carol D Karp, Wagner M Zago and Brandon S Smith. View institutional ownership trends. How do I buy shares of Prothena? Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Prothena own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prothena investors own include Cara Therapeutics (CARA), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT) and BioLineRx (BLRX). Company Calendar Last Earnings8/08/2024Today10/04/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRTA CUSIPN/A CIK1559053 Webwww.prothena.com Phone(531) 236-2500Fax353-1902-3510Employees130Year FoundedN/APrice Target and Rating Average Stock Price Target$61.86 High Stock Price Target$87.00 Low Stock Price Target$24.00 Potential Upside/Downside+268.2%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-147,030,000.00 Net Margins-23.44% Pretax Margin-28.26% Return on Equity-9.00% Return on Assets-7.51% Debt Debt-to-Equity RatioN/A Current Ratio12.54 Quick Ratio12.54 Sales & Book Value Annual Sales$91.37 million Price / Sales9.89 Cash FlowN/A Price / Cash FlowN/A Book Value$10.46 per share Price / Book1.61Miscellaneous Outstanding Shares53,780,000Free Float38,608,000Market Cap$903.50 million OptionableOptionable Beta0.18 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:PRTA) was last updated on 10/4/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredTrade Alongside Pelosi, Buffett, and MorePeople don't know that you can trade alongside politicians, lawmakers, and top investors like Warren Buffet, B...Bullseye Trades | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredNo matter the outcome of the election, it could be a death sentence for your wealth...In today's financial landscape, many investors are feeling disillusioned and disappointed with traditional inv...Allegiance Gold | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.